(GS71) GSK - Ratings and Ratios
Vaccines, Specialty Medicines, General Medicines, Oncology, Respiratory
GS71 EPS (Earnings per Share)
GS71 Revenue
Description: GS71 GSK
GSK plc, together with its subsidiaries, conducts research, development, and manufacturing of vaccines, specialty medicines, and general medicines for disease prevention and treatment across the United Kingdom, the United States, and global markets. The business is organized into two primary segments: Commercial Operations and Total R&D.
The Specialty Medicines segment covers oncology (e.g., ovarian and endometrial cancers), respiratory and immunology (e.g., eosinophil-driven asthma), inflammation, and inhaled therapies for HIV, lupus, and lupus nephritis. In FY 2023, this segment generated roughly £12 billion in revenue, representing about 35 % of total sales, and the oncology pipeline is projected to add an estimated £2 billion in incremental revenue by 2028 if current trial timelines hold.
GSK’s vaccine portfolio is extensive, including products for shingles (Shingrix), meningitis, RSV, seasonal influenza, hepatitis, diphtheria, tetanus, acellular pertussis, rotavirus, polio, Haemophilus invasive disease, pneumonia, acute otitis media, measles, mumps, rubella, chickenpox, and human papillomavirus. The company’s RSV vaccine candidate (Arexvy) entered the market in 2023 and has already captured a 15 % share of the U.S. pediatric RSV market, a key growth driver given the aging global population and heightened post-pandemic vaccine demand.
General medicines offered by GSK address asthma, COPD, bacterial infections, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. The firm also maintains a strategic collaboration with CureVac to co-develop mRNA vaccines for infectious diseases, reflecting a broader industry shift toward mRNA platforms that could accelerate time-to-market for future products.
Founded in 1715 and headquartered in London, the company rebranded from GlaxoSmithKline plc to GSK plc in May 2022. Its ticker on XETRA is GS71, classified under the Pharmaceuticals sub-industry. As of the latest reporting period, GSK reported a dividend yield of approximately 3.5 % and an R&D spend of £5.5 billion, underscoring its commitment to pipeline development amid a sector characterized by pricing pressure in the U.S. and robust demand for vaccines driven by demographic aging.
For a deeper, data-driven look at GSK’s valuation and peer benchmarks, you may find the detailed analysis on ValueRay worth exploring.
GS71 Stock Overview
| Market Cap in USD | 88,762m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
GS71 Stock Ratings
| Growth Rating | 46.8% |
| Fundamental | 76.1% |
| Dividend Rating | 21.4% |
| Return 12m vs S&P 500 | -4.48% |
| Analyst Rating | - |
GS71 Dividends
| Dividend Yield 12m | 4.42% |
| Yield on Cost 5y | 6.77% |
| Annual Growth 5y | -11.62% |
| Payout Consistency | 94.4% |
| Payout Ratio | 1.4% |
GS71 Growth Ratios
| Growth Correlation 3m | 89.5% |
| Growth Correlation 12m | 42.5% |
| Growth Correlation 5y | 60.2% |
| CAGR 5y | 10.01% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.36 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.06 |
| Sharpe Ratio 12m | 0.87 |
| Alpha | 2.08 |
| Beta | 0.294 |
| Volatility | 21.91% |
| Current Volume | 37.8k |
| Average Volume 20d | 144k |
| Stop Loss | 18.2 (-3.5%) |
| Signal | 0.56 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (3.42b TTM) > 0 and > 6% of Revenue (6% = 1.90b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -1.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.55% (prev -11.39%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 7.72b > Net Income 3.42b (YES >=105%, WARN >=100%) |
| Net Debt (12.19b) to EBITDA (9.99b) ratio: 1.22 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.05b) change vs 12m ago -0.80% (target <= -2.0% for YES) |
| Gross Margin 71.36% (prev 72.07%; Δ -0.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.92% (prev 54.16%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.29 (EBITDA TTM 9.99b / Interest Expense TTM 646.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.15
| (A) -0.05 = (Total Current Assets 17.67b - Total Current Liabilities 20.38b) / Total Assets 59.26b |
| (B) 0.15 = Retained Earnings (Balance) 8.80b / Total Assets 59.26b |
| (C) 0.11 = EBIT TTM 6.64b / Avg Total Assets 58.66b |
| (D) 0.20 = Book Value of Equity 8.80b / Total Liabilities 44.90b |
| Total Rating: 1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.05
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 5.95% = 2.98 |
| 3. FCF Margin 14.75% = 3.69 |
| 4. Debt/Equity 1.07 = 1.95 |
| 5. Debt/Ebitda 1.22 = 1.44 |
| 6. ROIC - WACC (= 26.05)% = 12.50 |
| 7. RoE 24.18% = 2.01 |
| 8. Rev. Trend 51.57% = 3.87 |
| 9. EPS Trend -37.77% = -1.89 |
What is the price of GS71 shares?
Over the past week, the price has changed by -0.32%, over one month by +11.30%, over three months by +16.05% and over the past year by +9.69%.
Is GSK a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GS71 is around 16.48 EUR . This means that GS71 is currently overvalued and has a potential downside of -12.62%.
Is GS71 a buy, sell or hold?
What are the forecasts/targets for the GS71 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 18 | -4.8% |
GS71 Fundamental Data Overview
Market Cap GBP = 66.09b (76.09b EUR * 0.8685 EUR.GBP)
P/E Trailing = 19.9105
P/E Forward = 8.5034
P/S = 2.4056
P/B = 4.4544
P/EG = 0.3847
Beta = 0.294
Revenue TTM = 31.63b GBP
EBIT TTM = 6.64b GBP
EBITDA TTM = 9.99b GBP
Long Term Debt = 13.70b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.18b GBP (from shortLongTermDebt, last fiscal year)
Debt = 15.88b GBP (Calculated: Short Term 2.18b + Long Term 13.70b)
Net Debt = 12.19b GBP (from netDebt column, last fiscal year)
Enterprise Value = 78.37b GBP (66.09b + Debt 15.88b - CCE 3.60b)
Interest Coverage Ratio = 10.29 (Ebit TTM 6.64b / Interest Expense TTM 646.0m)
FCF Yield = 5.95% (FCF TTM 4.67b / Enterprise Value 78.37b)
FCF Margin = 14.75% (FCF TTM 4.67b / Revenue TTM 31.63b)
Net Margin = 10.82% (Net Income TTM 3.42b / Revenue TTM 31.63b)
Gross Margin = 71.36% ((Revenue TTM 31.63b - Cost of Revenue TTM 9.06b) / Revenue TTM)
Gross Margin QoQ = 72.89% (prev 74.23%)
Tobins Q-Ratio = 1.32 (Enterprise Value 78.37b / Total Assets 59.26b)
Interest Expense / Debt = 1.16% (Interest Expense 184.0m / Debt 15.88b)
Taxrate = 12.77% (241.0m / 1.89b)
NOPAT = 5.80b (EBIT 6.64b * (1 - 12.77%))
Current Ratio = 0.87 (Total Current Assets 17.67b / Total Current Liabilities 20.38b)
Debt / Equity = 1.07 (Debt 15.88b / totalStockholderEquity, last quarter 14.79b)
Debt / EBITDA = 1.22 (Net Debt 12.19b / EBITDA 9.99b)
Debt / FCF = 2.61 (Net Debt 12.19b / FCF TTM 4.67b)
Total Stockholder Equity = 14.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.78% (Net Income 3.42b / Total Assets 59.26b)
RoE = 24.18% (Net Income TTM 3.42b / Total Stockholder Equity 14.16b)
RoCE = 23.85% (EBIT 6.64b / Capital Employed (Equity 14.16b + L.T.Debt 13.70b))
RoIC = 31.97% (NOPAT 5.80b / Invested Capital 18.13b)
WACC = 5.92% (E(66.09b)/V(81.97b) * Re(7.10%) + D(15.88b)/V(81.97b) * Rd(1.16%) * (1-Tc(0.13)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.12%
[DCF Debug] Terminal Value 75.48% ; FCFE base≈4.88b ; Y1≈4.10b ; Y5≈3.08b
Fair Price DCF = 14.03 (DCF Value 56.44b / Shares Outstanding 4.02b; 5y FCF grow -19.26% → 3.0% )
EPS Correlation: -37.77 | EPS CAGR: -53.92% | SUE: -0.05 | # QB: 0
Revenue Correlation: 51.57 | Revenue CAGR: 6.36% | SUE: N/A | # QB: 0